摘要
目的：观察布地奈德联合特布他林治疗支气管哮喘的临床疗效和安全性。方法：80例支气管哮喘患者随机均分为对照组和观察组。两组患者均给予常规综合治疗,包括吸氧、止咳、平喘、祛痰、抗感染等。在此基础上,对照组患者给予布地奈德混悬液1 ml（含布地奈德0.5 mg）加入2 ml 0.9%氯化钠注射液中雾化吸入,10~15 min/次,bid,早晚进行;观察组患者在对照组治疗的基础上给予特布他林雾化液1 ml（含特布他林2.5 mg）加入2 ml 0.9%氯化钠注射液中雾化吸入,10～15 min/次,bid,早晚进行。两组患者疗程均为7 d10观察两组患者的临床疗效,治疗前后肺功能指标[第1秒用力呼气容积（FEV1）、FEV1占预计值的百分比（FEV1%）、最大呼气峰流速（PEF）],临床症状消失时间（气促消失时间、憋喘消失时间、哮鸣音消失时间、咳嗽消失时间）及不良反应发生情况。结果：观察组患者总有效率显著高于对照组,两组比较差异有统计学意义（P〈0.05）。治疗前两组患者肺功能指标比较,差异均无统计学意义（P〉0.05）;治疗后两组患者肺功能指标均显著高于同组治疗前,且观察组高于对照组,差异均有统计学意义（P〈0.05）。观察组患者气促消失时间、憋喘消失时间、哮鸣音消失时间、咳嗽消失时间均显著短于对照组,两组比较差异有统计学意义（P〈0.05）。两组患者治疗期间均未见明显不良反应发生。结论：布地奈德联合特布他林治疗支气管哮喘较单用布地奈德疗效更好,安全性相似。
OBJECTIVE： To observe clinical efficacy and safety of budesonide combined with terbutaline in the treatment of bronchial asthma. METHODS ： 80 patients with bronchial asthma were randomly divided into control group and observation group. Both groups were given conventional therapy, including oxygen inhalation, relieving a cough and asthma, eliminating phlegm, an- ti-infection therapy, etc. Control group was additionally given aerosol inhalation of Budesonide suspension 1 ml （containing budesonide 0.5 mg） added into 2 ml 0.9% Sodium chloride injection, 10-15 min/time, twice a day, morning and night. Based on control group, observation group was additionally given Terbutaline atomized liquid 1 ml （containing terbutaline 2.5 mg） added into 2 ml 0.9% Sodium chloride injection, 10-15 min/time, twice a day, morning and night. Treatment course of 2 groups lasted for 7 days. Clinical efficacies of 2 groups were observed, and lung function index （FEV1, FEV1%, PEF）, the time of clinical symptom disappearance involving the time of anhelation disappearance, asthmatic and breath holding symptom disappearance, wheezing rale disappearance and cough disappearance, the occurrence of ADR were observed before and after treatment. RESULTS： Total effec- tive rate of observation group was significantly higher than that of control group; there was statistically significant difference （P〈 0.05）. Lung function index of 2 groups had no statistically significant difference before treatment （P〉0.05）. The lung function in- dex of 2 groups after treatment were all significantly higher than before, and the observation group was higher than the control group; there was statistically significant difference （P〈0.05）. The time of anhelation disappearance, asthmatic and breath holding symptom disappearance, wheezing rale disappearance and cough disappearance in observation group were significantly shorter than in control group; there was statistically significant difference （P〈0.05）. No obvious ADR was found in 2 groups during treatment. CONCLUSIONS： Budesonide combined with terbutaline is more effective than budesonide alone in the treatment of bronchial asth- ma, and they have similar safety.
出处
《中国药房》
CAS
北大核心
2015年第6期748-750,共3页
China Pharmacy
关键词
布地奈德
特布他林
支气管哮喘
疗效
安全性
Budesonide
Terbutaline
Bronchial asthma
Clinical efficacy
Safety
